Aroa Biosurgery Limited (ARX) Fair Value & Analysis
Healthcare · AU · Market cap A$224M
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from A$0.4600 to A$0.2000 (−56.5%) since Jun 23, 2026. Share price −13.9% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.5186 – A$0.8085 · fair‑value band A$0.1700 – A$0.2500 · the A$0.6000 price screens above the A$0.2000 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aroa Biosurgery Limited (ARX) currently trades at A$0.6000, while our model-based Fair Value estimate is A$0.2000 — implying the stock looks roughly 66.7% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Aroa Biosurgery Limited generated revenue of A$104M at a net margin of 4.5%. Revenue grew 29.5% year over year. It earns a return on equity of 4.9%. The balance sheet holds a net cash position of A$12.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, Ne…
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Aroa Biosurgery Limited reported revenue of A$92.3M in FY2026 versus A$36.9M in FY2022, a compound +25.8%/yr. Reported net income was A$4.2M in FY2026.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aroa Biosurgery Limited (ARX) undervalued?
What is the fair value of ARX?
What is the quality score of ARX?
What is the revenue of Aroa Biosurgery Limited (ARX)?
What is the net profit margin of ARX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.